1
|
Condé CASR, De Almeida MV, Da Silva GDS, Sodré MBPDA, Rodrigues JCF, Navarro M. Synthesis, characterization and antileishmanial activity of copper(II) and zinc(II) complexes with diamine ligands. TRANSIT METAL CHEM 2022. [DOI: 10.1007/s11243-022-00495-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Viana MDM, de Lima AA, da Silva Neto GJ, da Silva SMA, Leite AB, Dos Santos EC, Bassi ÊJ, Campesatto EA, de Queiroz AC, Barreiro EJ, Lima LM, Alexandre-Moreira MS. LASSBio-596: a New Pre-clinical Candidate for Rheumatoid Arthritis? Inflammation 2021; 45:528-543. [PMID: 34697722 DOI: 10.1007/s10753-021-01564-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Revised: 09/05/2021] [Accepted: 09/07/2021] [Indexed: 10/20/2022]
Abstract
Pain and inflammatory disorders are significant health problems because of prevalence and associated disabilities. In this context, LASSBio-596 is a hybrid compound able to modulate TNF-α and phosphodiesterases 4 and 5, exhibiting an anti-inflammatory effect in the pulmonary inflammatory model. Aiming at a better description of the activities of LASSBio-596, we initially conducted nociception tests (acetic acid-induced abdominal writhing, glutamate, and formalin-induced nociception and hot plate test) and later inflammatory tests (acute, peritonitis; and chronic, arthritis) that directed us to this last one. In the abdominal writhing test, there was a dose-dependent inhibition, whose response occurred at the maximum dose (50 mg/kg, p.o.), used in the subsequent tests. LASSBio-596 also inhibited nociception induced by chemical (glutamate by 31.9%; and formalin, in both phases, 1st phase: 25.7%; 2nd phase: 23.9%) and thermal agents (hotplate, by increased latency for pain at two different times). These effects were independent of the motor function, legitimated in rotarod. As there was a response in the inflammatory component of nociception, we performed the peritonitis test, in which migration was inhibited by LASSBio-596 by 39.9%. As the inflammatory process is present in autoimmune diseases, we also performed the arthritis test. LASSBio-596 reduced paw edema from the 15th day to the 21st day of treatment (no liver changes and with fewer paw injuries). In addition, LASSBio-596 decreased serum levels of TNF-α by 67.1%. These data demonstrated the antinociceptive effect of LASSBio-596 and reinforces its anti-inflammatory property (i.e., RA), amplifying the therapeutic potential of this molecule.
Collapse
Affiliation(s)
- Max Denisson Maurício Viana
- Pharmacology and Immunity Laboratory, Institute of Biological and Health Sciences, Federal University of Alagoas, Av. Lourival Melo Mota, SN, Tabuleiro do Martins, Maceio, AL, 57072-900, Brazil.
| | | | - Geraldo José da Silva Neto
- Laboratory of Catalysis and Chemical Reactivity, Institute of Chemistry and Biotechnology, Federal University of Alagoas, Maceio, AL, 57072-900, Brazil
| | - Suellen Maria Albuquerque da Silva
- Pharmacology and Immunity Laboratory, Institute of Biological and Health Sciences, Federal University of Alagoas, Maceio, AL, 57072-900, Brazil
| | - Anderson Brandão Leite
- Institute of Biological and Health Sciences, Federal University of Alagoas, Maceio, AL, 57072-900, Brazil
| | - Elane Conceição Dos Santos
- Immunoregulation Research Group, Laboratory of Research in Virology and Immunology, Institute of Biological and Health Sciences, Federal University of Alagoas, AL, 57072-900, Maceio, Brazil
| | - Ênio José Bassi
- Immunoregulation Research Group, Laboratory of Research in Virology and Immunology, Institute of Biological and Health Sciences, Federal University of Alagoas, AL, 57072-900, Maceio, Brazil
| | - Eliane Aparecida Campesatto
- Pharmacology and Immunity Laboratory, Institute of Biological and Health Sciences, Federal University of Alagoas, Maceio, AL, 57072-900, Brazil
| | - Aline Cavalcanti de Queiroz
- Microbiology, Immunology and Parasitology Laboratory, Medical and Nursing Sciences Complex, Federal University of Alagoas - Campus Arapiraca, Av. Manoel Severino Barbosa - Bom Sucesso, Arapiraca, AL, 57309-005, Brazil
| | - Eliezer Jesus Barreiro
- Laboratory for Evaluation and Synthesis of Bioactive Substances, LASSBio®, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, PO Box 68024, Rio de Janeiro, RJ, 21944-910, Brazil
| | - Lidia Moreira Lima
- Laboratory for Evaluation and Synthesis of Bioactive Substances, LASSBio®, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, PO Box 68024, Rio de Janeiro, RJ, 21944-910, Brazil
| | - Magna Suzana Alexandre-Moreira
- Pharmacology and Immunity Laboratory, Institute of Biological and Health Sciences, Federal University of Alagoas, Maceio, AL, 57072-900, Brazil
| |
Collapse
|
3
|
El-Zahabi MA, Sakr H, El-Adl K, Zayed M, Abdelraheem AS, Eissa SI, Elkady H, Eissa IH. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorg Chem 2020; 104:104218. [DOI: 10.1016/j.bioorg.2020.104218] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 06/04/2020] [Accepted: 08/22/2020] [Indexed: 01/06/2023]
|
4
|
Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A. Current pharmacological treatments for COVID-19: What's next? Br J Pharmacol 2020; 177:4813-4824. [PMID: 32329520 PMCID: PMC7264618 DOI: 10.1111/bph.15072] [Citation(s) in RCA: 165] [Impact Index Per Article: 41.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 04/16/2020] [Accepted: 04/17/2020] [Indexed: 12/15/2022] Open
Abstract
Since December 2019 SARS-Cov-2 was found responsible for the disease COVID-19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID-19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVID-19, focusing on their antiviral, immune-modulatory and/or anti-inflammatory actions. Where available, data from clinical trials involving patients with COVID-19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVID-19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
Collapse
Affiliation(s)
- Cristina Scavone
- Department of Experimental MedicineUniversità degli studi della Campania “Luigi Vanvitelli”NaplesItaly
| | - Simona Brusco
- Department of Experimental MedicineUniversità degli studi della Campania “Luigi Vanvitelli”NaplesItaly
| | - Michele Bertini
- Department of Experimental MedicineUniversità degli studi della Campania “Luigi Vanvitelli”NaplesItaly
| | - Liberata Sportiello
- Department of Experimental MedicineUniversità degli studi della Campania “Luigi Vanvitelli”NaplesItaly
| | - Concetta Rafaniello
- Department of Experimental MedicineUniversità degli studi della Campania “Luigi Vanvitelli”NaplesItaly
| | - Alice Zoccoli
- Clinical Innovation OfficeUniversità Campus Bio‐medicoRomeItaly
| | - Liberato Berrino
- Department of Experimental MedicineUniversità degli studi della Campania “Luigi Vanvitelli”NaplesItaly
| | - Giorgio Racagni
- Department of Pharmacological and Biomolecular SciencesUniversity of MilanMilanItaly
| | - Francesco Rossi
- Department of Experimental MedicineUniversità degli studi della Campania “Luigi Vanvitelli”NaplesItaly
- Clinical Innovation OfficeUniversità Campus Bio‐medicoRomeItaly
| | - Annalisa Capuano
- Department of Experimental MedicineUniversità degli studi della Campania “Luigi Vanvitelli”NaplesItaly
| |
Collapse
|
5
|
Godin AM, Araújo DP, Menezes RR, de Brito AMS, Melo ISF, Coura GME, Bastos LFS, Amaral FA, Teixeira MM, de Fátima Â, Coelho MM, Machado RR. 2-Phthalimidethanol and 2-phthalimidethyl nitrate inhibit mechanical allodynia, neutrophil recruitment and cytokine and chemokine production in a murine model of articular inflammation. Pharmacol Rep 2017; 69:691-695. [PMID: 28550800 DOI: 10.1016/j.pharep.2017.01.033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 01/16/2017] [Accepted: 01/30/2017] [Indexed: 12/31/2022]
Abstract
BACKGROUND Phthalimide analogs have been shown to exhibit anti-inflammatory, analgesic and immunomodulatory activities in different preclinical assays. This study aimed to investigate the potential role of 2-phthalimidethanol (PTD-OH) and 2-phthalimidethyl nitrate (PTD-NO) in a murine model of antigen-induced articular inflammation. METHODS Articular inflammation was induced by intra-articular injection of methylated bovine serum albumin (mBSA) in the knee joint of immunized male C57BL/6J mice. The animals were pre-treated with PTD-OH or PTD-NO (500mg/kg, per os, - 1h). Nociceptive threshold was measured using an electronic von Frey apparatus. The total number of leukocytes in the synovial cavity was determined. Concentrations of tumor necrosis factor (TNF)-α and CXCL-1 and myeloperoxidase (MPO) activity were determined in periarticular tissue. RESULTS Both PTD-OH and PTD-NO inhibited at similar extent the mechanical allodynia, neutrophil recruitment to the synovial cavity and periarticular tissue and TNF-α and CXCL-1 production induced by intra-articular challenge with mBSA in immunized mice. CONCLUSIONS PTD-OH and PTD-NO exhibit a marked activity in a murine model of antigen-induced articular inflammation in immunized animals. These results reinforce the interest in the investigation of phthalimide analogs devoid of the glutarimide ring as candidates to analgesic and anti-inflammatory drugs.
Collapse
Affiliation(s)
- Adriana M Godin
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Débora P Araújo
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Raquel R Menezes
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Ana M S de Brito
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Ivo S F Melo
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Giovanna M E Coura
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Leandro F S Bastos
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Flávio A Amaral
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Mauro M Teixeira
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Ângelo de Fátima
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Márcio M Coelho
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Renes R Machado
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
| |
Collapse
|
6
|
Abstract
Thalidomide and its derivatives are currently under investigation for their antiangiogenic, immunomodulative, and anticancer properties. Current methods used to synthesize these compounds involve multiple steps and extensive workup procedures. Described herein is an efficient microwave irradiation green synthesis method that allows preparation of thalidomide and its analogs in a one-pot multicomponent synthesis system. The multicomponent synthesis system developed involves an array of cyclic anhydrides, glutamic acid, and ammonium chloride in the presence of catalytic amounts of 4-N,N-dimethylaminopyridine (DMAP) to produce thalidomide and structurally related compounds within minutes in good isolated yields.
Collapse
|
7
|
Viswanathan P, Gupta P, Kapoor S, Gupta S. Thalidomide promotes transplanted cell engraftment in the rat liver by modulating inflammation and endothelial integrity. J Hepatol 2016; 65:1171-1178. [PMID: 27422749 PMCID: PMC5116265 DOI: 10.1016/j.jhep.2016.07.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Revised: 05/26/2016] [Accepted: 07/04/2016] [Indexed: 12/28/2022]
Abstract
BACKGROUND & AIMS For liver-directed cell therapy, efficient engraftment of transplanted cells is critical. This study delineated whether anti-inflammatory and endothelial disrupting properties of thalidomide could promote transplanted cell engraftment and proliferation in liver. METHODS We used dipeptidyl peptidase IV-deficient rats for cell transplantation studies, including gene expression analysis, morphological tissue analysis, serological assays, cell culture assays, and assays of transplanted cell engraftment and proliferation. RESULTS Thalidomide-pretreatment increased engraftment and proliferation of transplanted hepatocytes due to decreased inflammation. Moreover, thalidomide exacerbated cell transplantation-induced endothelial injury. This combined anti-inflammatory and endothelial injury effect of thalidomide was superior to the anti-inflammatory effect alone of repertaxin or etanercept, which block cytokines/chemokines/receptor-dependent inflammation. In thalidomide-pretreated animals, liver repopulation accelerated, including when cells were primed with bosentan to block endothelin-1 receptors. CONCLUSIONS Thalidomide improved transplanted cell engraftment and liver repopulation. Therefore, this class of drugs will advance applications of liver cell therapy in people. LAY SUMMARY This work aimed to develop effective drug treatments for improving engraftment of transplanted cells because that constitutes a critical step in rebuilding liver with healthy cells. Studies in animal models of cell transplantation led to identification of an old drug, thalidomide, which blocked inflammation and altered the liver microenvironment to yield superior engraftment and proliferation of transplanted cells. This will be appropriate for liver cell therapy in people.
Collapse
Affiliation(s)
- Preeti Viswanathan
- Division of Pediatric Gastroenterology, Department of Pediatrics, Children’s Hospital at Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Priya Gupta
- Department of Medicine, Albert Einstein College of Medicine, Bronx, NY
| | - Sorabh Kapoor
- Department of Medicine, Albert Einstein College of Medicine, Bronx, NY
| | - Sanjeev Gupta
- Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States; Departments of Medicine and Pathology, Marion Bessin Liver Research Center, Diabetes Center, Cancer Center, Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY, United States.
| |
Collapse
|
8
|
Godin AM, Araújo DP, César IC, Menezes RR, Brito AMS, Melo ISF, Coura GME, Bastos LFS, Almeida MO, Byrro RMD, Matsui TC, Batista CRA, Pianetti GA, de Fátima Â, Machado RR, Coelho MM. Activities of 2-phthalimidethyl nitrate and 2-phthalimidethanol in the models of nociceptive response and edema induced by formaldehyde in mice and preliminary investigation of the underlying mechanisms. Eur J Pharmacol 2015; 756:59-66. [PMID: 25794846 DOI: 10.1016/j.ejphar.2015.02.052] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Revised: 02/03/2015] [Accepted: 02/22/2015] [Indexed: 01/23/2023]
Abstract
The activities of 2-phthalimidethyl nitrate (PTD-NO) and 2-phthalimidethanol (PTD-OH) were recently demonstrated in models of pain and inflammation. We expanded our investigation by evaluating their activities in models of nociceptive and inflammatory pain and inflammatory edema, the preliminary pharmacokinetic parameter for PTD-NO and the role of opioid and cannabinoid pathways in the activity of analogs. Per os (p.o.) administration of PTD-NO or PTD-OH, 1h before intraplantar injection of formaldehyde, inhibited both phases of the nociceptive response (500 and 750 mg/kg) and paw edema (125, 250, 500 and 750 mg/kg). After p.o. administration of PTD-NO, peak plasma concentrations of PTD-NO and PTD-OH were found 0.92 and 1.13 h, respectively. The plasma concentrations of PTD-NO were higher than those of PTD-OH. Intraperitoneal (i.p.) administration of CB1 (AM251) or CB2 (AM630) cannabinoid receptor antagonists (4 or 8 mg/kg, -30 min) or opioid antagonist naltrexone (5 or 10mg/kg, -30 min) did not affect the antinociceptive activities of the analogs. AM251 (8 mg/kg, i.p., -30 min) attenuated the antiedematogenic activity of both analogs, while naltrexone (10mg/kg, i.p., -30 min) only attenuated the antiedematogenic activity of PTD-NO. The antiedematogenic activities of both analogs were not affected by the CB2 cannabinoid antagonist AM630 (4 or 8 mg/kg, i.p., -30 min). Concluding, we expanded the knowledge on the activities of PTD-NO and PTD-OH by showing that these phthalimide analogs also exhibit marked activity in models of nociceptive and inflammatory pain and inflammatory edema. Opioid and cannabinoid mechanisms partially mediate the anti-inflammatory, but not the antinociceptive activity.
Collapse
Affiliation(s)
- Adriana M Godin
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Débora P Araújo
- Departamento de Química, Instituto de Ciências Exatas Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Isabela C César
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Raquel R Menezes
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Ana Mercy S Brito
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Ivo S F Melo
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Giovanna M E Coura
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Leandro F S Bastos
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Mariana O Almeida
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Ricardo M D Byrro
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Tamires C Matsui
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Carla R A Batista
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Gerson A Pianetti
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Ângelo de Fátima
- Departamento de Química, Instituto de Ciências Exatas Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Renes R Machado
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Márcio M Coelho
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP, 31270-901 Belo Horizonte, Minas Gerais, Brazil.
| |
Collapse
|
9
|
FERREIRA PAULOMICHELPINHEIRO, COSTA PATRICIAMARÇALDA, COSTA ARINICEDEMENEZES, LIMA DAISYJEREISSATIBARBOSA, DRUMOND RENATAROSADO, SILVA JURANDYDONASCIMENTO, MOREIRA DIOGORODRIGODEMAGALHÃES, OLIVEIRA FILHO GEVÂNIOBEZERRADE, FERREIRA JAMILEMAGALHÃES, QUEIROZ MARIAGORETTIRODRIGUESDE, LEITE ANACRISTINALIMA, PESSOA CLÁUDIA. Cytotoxic and toxicological effects of phthalimide derivatives on tumor and normal murine cells. ACTA ACUST UNITED AC 2015; 87:313-30. [DOI: 10.1590/0001-3765201520130345] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Accepted: 08/06/2014] [Indexed: 11/22/2022]
Abstract
Eleven phthalimide derivatives were evaluated with regards to their antiproliferative activity on tumor and normal cells and possible toxic effects. Cytotoxic analyses were performed against murine tumors (Sarcoma 180 and B-16/F-10 cells) and peripheral blood mononuclear cells (PBMC) using MTT and Alamar Blue assays. Following, the investigation of cytotoxicity was executed by flow cytometry analysis and antitumoral and toxicological potential by in vivo techniques. The molecules 3b, 3c, 4 and 5 revealed in vitro cytotoxicity against Sarcoma 180, B-16/F-10 and PBMC. Since compound 4 was the most effective derivative, it was chosen to detail the mechanism of action after 24, 48 and 72 h exposure (22.5 and 45 µM). Sarcoma 180 cells treated with compound 4 showed membrane disruption, DNA fragmentation and mitochondrial depolarization in a time- and dose-dependent way. Compounds 3c, 4 and 5 (50 mg/kg/day) did not inhibit in vivotumor growth. Compound 4-treated animals exhibited an increase in total leukocytes, lymphocytes and spleen relative weight, a decreasing in neutrophils and hyperplasia of spleen white pulp. Treated animals presented reversible histological changes. Molecule 4 had in vitro antiproliferative action possibly triggered by apoptosis, reversible toxic effects on kidneys, spleen and livers and exhibited immunostimulant properties that can be explored to attack neoplasic cells.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - CLÁUDIA PESSOA
- Universidade Federal do Ceará, Brasil; Fundação Oswaldo Cruz, Brasil
| |
Collapse
|
10
|
Godin AM, Araújo DP, Menezes RR, Brito AMS, Melo ISF, Coura GME, Soares DG, Bastos LFS, Amaral FA, Ribeiro LS, Boff D, Santos JRA, Santos DA, Teixeira MM, de Fátima Â, Machado RR, Coelho MM. Activities of 2-phthalimidethanol and 2-phthalimidethyl nitrate, phthalimide analogs devoid of the glutarimide moiety, in experimental models of inflammatory pain and edema. Pharmacol Biochem Behav 2014; 122:291-8. [PMID: 24780502 DOI: 10.1016/j.pbb.2014.04.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Revised: 04/08/2014] [Accepted: 04/18/2014] [Indexed: 12/17/2022]
Abstract
The reintroduction of thalidomide in the pharmacotherapy greatly stimulated the interest in the synthesis and pharmacological evaluation of phthalimide analogs with new and improved activities and also greater safety. In the present study, we evaluated the activities of two phthalimide analogs devoid of the glutarimide ring, namely 2-phthalimidethanol (PTD-OH) and 2-phthalimidethyl nitrate (PTD-NO), in experimental models of inflammatory pain and edema in male C57BL/6J mice. Intraplantar (i.pl.) injection of carrageenan (300 μg) induced mechanical allodynia and this response was inhibited by previous per os (p.o.) administration of PTD-OH and PTD-NO (750 mg/kg) and also by thalidomide (500 or 750 mg/kg). The edema induced by carrageenan was also inhibited by previous p.o. administration of PTD-OH (500 and 750 mg/kg) and PTD-NO (125, 250, 500 or 750 mg/kg), but not by thalidomide. Carrageenan increased tumor necrosis factor (TNF)-α and CXCL1 concentrations and also the number of neutrophils in the paw tissue. Previous p.o. administration of PTD-NO (500 mg/kg) reduced all the parameters, while PTD-OH (500 mg/kg) reduced only the accumulation of neutrophils. Thalidomide, on the other hand, was devoid of effect on these biochemical parameters. Plasma concentrations of nitrite were increased after p.o. administration of the phthalimide analog coupled to a NO donor, PTD-NO (500 mg/kg), but not after administration of PTD-OH or thalidomide. In conclusion, our results show that small molecules, structurally much simpler than thalidomide or many of its analogs under investigation, exhibit similar activities in experimental models of pain and inflammation. Finally, as there is evidence that the glutarimide moiety contributes to the teratogenic effect of many thalidomide analogs, our results indicate that phthalimide analogs devoid of this functional group could represent a new class of analgesic and anti-inflammatory candidates with potential greater safety.
Collapse
Affiliation(s)
- Adriana M Godin
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Débora P Araújo
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Raquel R Menezes
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Ana Mercy S Brito
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Ivo S F Melo
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Giovanna M E Coura
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Darly G Soares
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Leandro F S Bastos
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Flávio A Amaral
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Lucas S Ribeiro
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Daiane Boff
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Julliana R A Santos
- Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Daniel A Santos
- Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Mauro M Teixeira
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Ângelo de Fátima
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Renes R Machado
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil
| | - Márcio M Coelho
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha CEP 31270-901, Belo Horizonte, MG, Brazil.
| |
Collapse
|
11
|
Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai) 2014; 46:240-53. [PMID: 24374776 DOI: 10.1093/abbs/gmt142] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular mechanism of IMiDs' action is largely unknown. In this review, we will summarize recent advances in the application of IMiDs in MM cancer treatment as well as their effects on immunomodulatory activities, anti-angiogenic activities, intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells, anti-inflammatory activities, anti-proliferation, pro-apoptotic effects, cell cycle arrest, and inhibition of cell migration and metastasis. In addition, the potential IMiDs' target protein, IMiDs' target protein's functional role, and the potential molecular mechanisms of IMiDs resistance will be discussed. We wish, by presentation of our naive discussion, that this review article will facilitate further investigation in these fields.
Collapse
Affiliation(s)
- Xiubao Chang
- Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
| | | | | | | |
Collapse
|
12
|
Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Med Chem 2013; 5:961-78. [PMID: 23682571 DOI: 10.4155/fmc.13.62] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Throughout the history of human civilizations, cancer has been a major health problem. Its treatment has been interesting but challenging to scientists. Glutamic acid and its derivative glutamine are known to play interesting roles in cancer genesis, hence, it was realized that structurally variant glutamic acid derivatives may be designed and developed and, might be having antagonistic effects on cancer. The present article describes the state-of-art of glutamic acid and its derivatives as anticancer agents. Attempts have been made to explore the effectivity of drug-delivery systems based on glutamic acid for the delivery of anticancer drugs. Moreover, efforts have also been made to discuss the mechanism of action of glutamic acid derivatives as anticancer agents, clinical applications of glutamic acid derivatives, as well as recent developments and future perspectives of glutamic acid drug development have also been discussed.
Collapse
|
13
|
Reis EF, Castro SB, Alves CCS, Oliveira EE, Corrêa TA, Almeida MV, Ferreira AP. Lipophilic amino alcohols reduces carrageenan-induced paw edema and anti-OVA DTH in BALB/c mice. Int Immunopharmacol 2013; 17:727-32. [DOI: 10.1016/j.intimp.2013.08.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2013] [Revised: 08/12/2013] [Accepted: 08/27/2013] [Indexed: 10/26/2022]
|
14
|
Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease. PLoS One 2013; 8:e55091. [PMID: 23405115 PMCID: PMC3566218 DOI: 10.1371/journal.pone.0055091] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2012] [Accepted: 12/21/2012] [Indexed: 01/18/2023] Open
Abstract
Thalidomide is a tumor necrosis factor alpha (TNFα) inhibitor which has been found to have abilities against tumor growth, angiogenesis and inflammation. Recently, it has been applied in clinic for the treatment of multiple myeloma as well as some inflammatory diseases. However, whether thalidomide has any therapeutic effects on neurodegenerative disorders, i.e. Alzheimer’s disease (AD) is not clear. AD is characterized by excessive amount of amyloid β peptides (Aβ), which results in a significant release of inflammatory factors, including TNFα in the brain. Studies have shown that inhibition of TNFα reduces amyloid-associated pathology, prevents neuron loss and improves cognition. Our recent report showed that genetic inhibition of TNFα/TNF receptor signal transduction down-regulates β amyloid cleavage enzyme 1 (BACE1) activity, reduces Aβ generation and improves learning and memory deficits. However, the mechanism of thalidomide involving in the mitigation of AD neuropathological features remains unclear. Here, we chronically administrated thalidomide on human APPswedish mutation transgenic (APP23) mice from 9 months old (an onset of Aβ deposits and early stage of AD-like changes) to 12 months old. We found that, in addition of dramatic decrease in the activation of both astrocytes and microglia, thalidomide significantly reduces Aβ load and plaque formation. Furthermore, we found a significant decrease in BACE1 level and activity with long-term thalidomide application. Interestingly, these findings cannot be observed in the brains of 12-month-old APP23 mice with short-term treatment of thalidomide (3 days). These results suggest that chronic thalidomide administration is an alternative approach for AD prevention and therapeutics.
Collapse
|